scholarly journals Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers

Oncotarget ◽  
2015 ◽  
Vol 6 (7) ◽  
pp. 5147-5163 ◽  
Author(s):  
Feng Li ◽  
Muthu K. Shanmugam ◽  
Kodappully Sivaraman Siveen ◽  
Fan Wang ◽  
Tina H. Ong ◽  
...  
Keyword(s):  
Mouse Model ◽  
Head And Neck ◽  
Head And Neck Carcinoma ◽  
Human Head ◽  
Xenograft Mouse Model ◽  
Neck Carcinoma

Abstract 1127: Aberrant nuclear expression of GSK-3beta in human head and neck carcinoma

2017 ◽  
Author(s):  
Maria Matsangou ◽  
Andrey Ugolkov ◽  
Timothy J. Taxter ◽  
Sandeep Samant ◽  
Andrew P. Mazar ◽  
...  
Keyword(s):  
Head And Neck ◽  
Head And Neck Carcinoma ◽  
Human Head ◽  
Nuclear Expression ◽  
Neck Carcinoma

scholarly journals Activity of the Vascular-Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid against Human Head and Neck Carcinoma Xenografts

Neoplasia ◽  
2006 ◽  
Vol 8 (7) ◽  
pp. 534-542 ◽  
Author(s):  
Mukund Seshadri ◽  
Richard Mazurchuk ◽  
Joseph A. Spernyak ◽  
Arup Bhattacharya ◽  
Youcef M. Rustum ◽  
...  
Keyword(s):  
Acetic Acid ◽  
Head And Neck ◽  
Head And Neck Carcinoma ◽  
Human Head ◽  
Vascular Disrupting Agent ◽  
Neck Carcinoma ◽  
Vascular Disrupting

scholarly journals Bortezomib sensitizes human head and neck carcinoma cells SQ20B to radiation

2007 ◽  
Vol 6 (2) ◽  
pp. 156-159 ◽  
Author(s):  
Charles N. Weber ◽  
George J. Cerniglia ◽  
Amit Maity ◽  
Anjali K. Gupta
Keyword(s):  
Head And Neck ◽  
Head And Neck Carcinoma ◽  
Human Head ◽  
Carcinoma Cells ◽  
Neck Carcinoma

Lack of effect of palifermin on the anti-tumor activity of cisplatin, cetuximab or panitumumab in the FaDu human head and neck carcinoma model

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 6060-6060
Author(s):  
L. Borges ◽  
R. Brake ◽  
R. Radinsky ◽  
C. Starnes
Keyword(s):  
Head And Neck ◽  
Tumor Volume ◽  
Xenograft Model ◽  
Head And Neck Carcinoma ◽  
Human Head ◽  
Therapeutic Modalities ◽  
Pharyngeal Carcinoma ◽  
Neck Carcinoma ◽  
Significant Difference ◽  
Anti Tumor Activity

6060 Background: The FaDu human pharyngeal carcinoma cell line expresses the receptors for both KGF and EGF. Palifermin is a recombinant form of human KGF. The objective of this study was to determine whether the combination of palifermin with cisplatin and the EGFR inhibitors cetuximab or panitumumab interferes with the anti-tumor activities of these agents in the FaDu head and neck xenograft model. Methods: FaDu tumor cells were implanted subcutaneously in CD1 nude mice. For the combination of palifermin with cetuximab and cisplatin, treatment began on day 9 and for the combination of palifermin with panitumumab and cisplatin, treatment began on day 10. The primary endpoint was the measure of tumor volume. Results: There was no statistically significant difference in tumor volume between the control arm and palifermin alone (p = 0.9993, 0.9831). Neither was there a statistically significant difference between the combination of palifermin, cisplatin and cetuximab compared to the combination of cisplatin and cetuximab (p = 0.7730). Similarly, there was no significant difference between the combination of palifermin, cisplatin and panitumumab compared to the combination of cisplatin and panitumumab (p = 0.9739). Conclusions: In drug combination settings, the addition of palifermin did not affect the therapeutic efficacy of cisplatin, cetuximab or panitumumab in any of the two- or three-way drug combinations. When used alone, palifermin did not promote the growth of the FaDu human xenograft despite the fact that these tumors express KGFR. The lack of interference of palifermin with the anti-tumor activity of cisplatin and the anti-EGFR target therapeutics suggests it is appropriate to move forward clinically investigating the use of palifermin in solid tumor settings in which these therapeutic modalities are used. No significant financial relationships to disclose.

Enhanced IκB kinase activity is responsible for the augmented activity of NF-κB in human head and neck carcinoma cells

2001 ◽  
Vol 171 (2) ◽  
pp. 165-172 ◽  
Author(s):  
Tetsuya Tamatani ◽  
Masayuki Azuma ◽  
Keiko Aota ◽  
Tsuyoshi Yamashita ◽  
Takashi Bando ◽  
...  
Keyword(s):  
Head And Neck ◽  
Kinase Activity ◽  
Head And Neck Carcinoma ◽  
Human Head ◽  
Carcinoma Cells ◽  
Iκb Kinase ◽  
Neck Carcinoma

Growth and Chemosensitivity of Human Head and Neck Cancers Implanted under the Kidney Capsule of Cyclosporine-Immunosuppressed Mice

1989 ◽  
Vol 98 (6) ◽  
pp. 455-460 ◽  
Author(s):  
James A. Bennett ◽  
Steven M. Parnes ◽  
Ronald C. DeConti
Keyword(s):  
Head And Neck ◽  
Clinical Response ◽  
Drug Testing ◽  
Head And Neck Carcinoma ◽  
Human Head ◽  
Kidney Capsule ◽  
Neck Carcinoma ◽  
Transplant Generation ◽  
Immunosuppressed Mice ◽  
Selection Of

Thirty-seven of 54 human squamous cell head and neck carcinomas were grown successfully as first transplant generation xenografts under the kidney capsule of conventional mice immunosuppressed by daily treatment with 60 mg/kg of cyclosporine. Eighteen different tumors were evaluated for chemosensitivity to cis-diamminedichloroplatinum (cisplatin), 5-fluorouracil, and methotrexate. Thirty-nine percent of the tumors responded to cisplatin, 19% to 5-fluorouracil, and 33% to methotrexate. This assay response is consistent with the clinical response of human squamous head and neck carcinoma to these drugs used as single agents. It is hoped that this model will become useful for new drug testing and, in certain cases, for selection of chemotherapy for patients with refractory tumors.

scholarly journals Efficacy of Combining GMX1777 with Radiation Therapy for Human Head and Neck Carcinoma

2010 ◽  
Vol 16 (3) ◽  
pp. 898-911 ◽  
Author(s):  
H. Kato ◽  
E. Ito ◽  
W. Shi ◽  
N. M. Alajez ◽  
S. Yue ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Head And Neck ◽  
Head And Neck Carcinoma ◽  
Human Head ◽  
Neck Carcinoma
Sign in / Sign up

Export Citation Format

Share Document